Latest From the NEOTORCH Trial & KEYNOTE-671 Trial


Experts review the NEOTORCH study of 400 patients showing favorable outcomes with a hazard ratio for event-free survival of 0.4.

This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.

Forde and Cascone discuss 2 additional perioperative treatment options for non–small cell lung cancer (NSCLC) from the NEOTORCH study and the KEYNOTE-671 trial.

The NEOTORCH trial, conducted predominantly in China, evaluated the anti-PD1 agent toripalimab. Patients received 3 cycles of chemotherapy plus immunotherapy preoperatively, followed by an additional cycle postoperatively and maintenance toripalimab. The results showed a significantly improved event-free survival (EFS) HR of 0.4, improved pathologic and patient response rates of about 24%, and a strong trend towards overall survival (OS). This study highlights the potential for exploring different schedules and regimens in the perioperative setting.

KEYNOTE-671 had dual primary endpoints of EFS and OS. With a follow-up of 36.6 months, the trial demonstrated an EFS HR of 0.59 and a significant and clinically meaningful OS HR of 0.72 in favor of the perioperative pembrolizumab arm. While patients who achieve pathologic complete response (pCR) benefit from this therapy, some patients without pCR may also benefit from continuing treatment.

Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.

Related Videos
Video 2 - "Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease"
Video 1 - "Patient Case: Pathology of Graft Versus Host Disease"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"